Mineralys Therapeutics insider files planned stock sale

Mineralys Therapeutics, Inc. has a planned sale of common stock by an affiliate through Merrill Lynch on NASDAQ, related to an exercise of employee stock options using a broker-assisted cashless exercise on 07/13/2026.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. has a planned sale of common stock by an affiliate through Merrill Lynch on NASDAQ, related to an exercise of employee stock options using a broker-assisted cashless exercise on 07/13/2026. In the prior three months, David Rodman reported multiple open-market sales of the company’s common stock on various dates in April, May, June, and July 2026, with individual transactions ranging from a few hundred to over 14,000 shares and aggregate dollar values per trade from tens of thousands to over $400,000.

Filing Explained

The July 13 filing records a proposed 14,058-share disposition, not a completed sale or disclosed issuer-level change.

The July 13, 2026 Form 144 identifies a proposed sale by David Rodman of 14,058 shares of Mineralys Therapeutics common stock through a broker-assisted cashless exercise of employee stock options; the filing does not state that this proposed sale has occurred.

The filing separately reports 14,058 common shares as securities to be sold and lists 82,498,101 shares as outstanding in its securities information, so it documents a filer-level planned transaction rather than a completed issuer-level issuance, sale, or receipt of proceeds.

Its securities-sold-during-the-past-three-months section records David Rodman sales from April 13, 2026 through July 9, 2026, including 2,171 shares sold on July 9, 2026 for $65,781.30.

The unresolved step is whether the 14,058 identified securities are actually sold; the filing reports them as securities to be sold and gives no completed-sale date for that entry.

Key Figures

Shares Outstanding: 82,498,101 shares Sale on 04/13/2026: 14,058 shares for $373,086.81 Sale on 05/13/2026: 14,056 shares for $401,789.92 +2 more

5 metrics

Shares Outstanding 82,498,101 shares Common stock outstanding as referenced in the Form 144

Sale on 04/13/2026 14,058 shares for $373,086.81 Common stock sold by David Rodman on 04/13/2026

Sale on 05/13/2026 14,056 shares for $401,789.92 Common stock sold by David Rodman on 05/13/2026

Sale on 06/15/2026 9,890 shares for $235,487.24 Common stock sold by David Rodman on 06/15/2026

Sale on 06/17/2026 4,584 shares for $114,600.00 Common stock sold by David Rodman on 06/17/2026

Key Terms

Form 144, Exercise of employee stock options, broker assisted cashless exercise, Common stock

4 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of employee stock options financial

"Common Stock | 07/13/2026 | Exercise of employee stock options"

broker assisted cashless exercise financial

"14058 | 07/13/2026 | Broker assisted cashless exercise"

Common stock financial

"Common Stock | 04/13/2026 | 14058 | 373086.81"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mineralys Therapeutics (MLYS) report in this Form 144?

Mineralys Therapeutics reports a planned sale of common stock on NASDAQ by an affiliate, tied to an exercise of employee stock options via a broker-assisted cashless exercise on 07/13/2026.

Who is the selling security holder in the Mineralys Therapeutics (MLYS) Form 144?

The selling security holder disclosed is David Rodman, with an address in Radnor, Pennsylvania, who has reported multiple common stock sales of Mineralys Therapeutics, Inc. during the past three months.

What recent stock sales by David Rodman are disclosed for MLYS?

Disclosed sales include trades such as 14,058 shares on 04/13/2026 for $373,086.81 and 14,056 shares on 05/13/2026 for $401,789.92, among several smaller transactions between April and July 2026.

What was the largest individual transaction value reported for MLYS stock?

Among the listed transactions, the largest individual aggregate value is $401,789.92 from a sale of 14,056 shares of Mineralys Therapeutics common stock on 05/13/2026.

How many Mineralys Therapeutics (MLYS) shares are indicated as outstanding?

The filing indicates that Mineralys Therapeutics has 82,498,101 shares of common stock outstanding, providing context for the relative size of the reported sales by the affiliate holder.

What is a broker-assisted cashless exercise in the MLYS Form 144?

A broker-assisted cashless exercise allows option holders to exercise employee stock options and simultaneously sell enough shares through a broker to cover the exercise cost, with the balance typically delivered as shares or cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001672659
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Rodman David Malcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14508	387716.51	82498101	07/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/13/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			14058	07/13/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PA 19087	Common Stock	04/13/2026	14058	373086.81
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/15/2026	6348	175585.68
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/17/2026	416	13033.28
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/11/2026	2171	64500.41
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/12/2026	6348	186348.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/13/2026	14056	401789.92
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/18/2026	417	11488.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/10/2026	2170	54250.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/12/2026	6349	151901.37
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/15/2026	9890	235487.24
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/17/2026	4584	114600.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/09/2026	2171	65781.30

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	David Rodman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)